Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
复制标题
纪念斯隆·克特林癌症中心的精密医学：临床下一代测序实现下一代目标治疗试验。
DOI：
10.1016/j.drudis.2015.08.005
复制
发表时间：
2015-12
影响因子：
7.4
通讯作者：
Ladanyi M
中科院分区：
文献类型：
--
作者：
Hyman DM;Solit DB;Arcila ME;Cheng DT;Sabbatini P;Baselga J;Berger MF;Ladanyi M
在大型癌症中心实施中心范围的精准医学战略是一项真正的多学科努力，需要广泛的筛查战略与临床研究企业的全面协调，该企业可以使用这些数据来加速新疗法的开发。在这里，我们描述了纪念斯隆-凯特琳癌症中心的基因组筛选方法，这是一种基于杂交捕获的新一代实体肿瘤分子肿瘤学测序临床分析方法，名为MSK-Impact，以及它如何启用和支持丰富的大型临床试验组合，以丰富靶向治疗的多组织学、生物标记物选择、‘篮子’研究。
Implementing a center-wide precision medicine strategy at a major cancer center is a true multidisciplinary effort and requires comprehensive alignment of a broad screening strategy with a clinical research enterprise that can use these data to accelerate development of new treatments. Here, we describe the genomic screening approach at Memorial Sloan Kettering Cancer Center, a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology designated MSK-IMPACT, and how it enables and supports a large clinical trial portfolio enriched for multi-histology, biomarker-selected, ‘basket’ studies of targeted therapies.